Article Information
History
- August 16, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Carlos Loucera1,2,
- Rosario Carmona1,2,3,
- Marina Esteban-Medina1,2,
- Gerrit Bostelmann1,
- Dolores Muñoyerro-Muñiz4,
- Román Villegas4,
- María Peña-Chilet1,2,3 and
- Joaquin Dopazo1,2,3,5,*
- 1Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Sevilla, 41013, Spain
- 2Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, Spain
- 3Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). FPS. Hospital Virgen del Rocio. 41013. Sevilla. Spain
- 4Subdirección Técnica Asesora de Gestión de la Información. Servicio Andaluz de Salud. 41071, Sevilla, Spain
- 5FPS/ELIXIR-ES, Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain
- ↵* Corresponding author; email: joaquin.dopazo{at}juntadeandalucia.es
Posted August 16, 2022.
Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk
